Replies to post #173652 on Biotech Values

[biomaven0]

I do agree that overall safety and efficacy look broadly comparable.

My sense though is that it would make a big difference for the ABBV regimen if there was at least one subgroup where it shows (or at least appears to show) a distinct advantage over the GILD offerings. You agree that we can't determine that yet based on the data we know to date?

Peter